{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:23:31Z","timestamp":1778768611408,"version":"3.51.4"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"financial travel support from Medac, BMS Celgene"},{"DOI":"10.13039\/100008792","name":"Novartis | Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007163","name":"Therakos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007163","id-type":"DOI","asserted-by":"publisher"}]},{"name":"honoraria from Incyte, Sanofi, Neovii and Behring."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41409-025-02778-w","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T17:14:56Z","timestamp":1765905296000},"page":"322-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multicenter validation of the newly developed Concise Objectifiable Risk Evaluation (CORE) score also confirms its ability to complement the Hematopoietic Cell Comorbidity Index (HCT-CI)"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4546-7650","authenticated-orcid":false,"given":"Gunnar","family":"Weise","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0611-1372","authenticated-orcid":false,"given":"Christina","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Denk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9275-3840","authenticated-orcid":false,"given":"Radwan","family":"Massoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Meedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-3190","authenticated-orcid":false,"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-1847","authenticated-orcid":false,"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"2778_CR1","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156\u201364.","journal-title":"Blood"},{"key":"2778_CR2","doi-asserted-by":"publisher","first-page":"1011.e1","DOI":"10.1016\/j.jtct.2024.07.026","volume":"30","author":"N Gagelmann","year":"2024","unstructured":"Gagelmann N, Schuh C, Zeiser R, Stelljes M, Bethge W, Wulf G, et al. Allogeneic Hematopoietic cell transplantation for myelofibrosis aged 70 years or older: A Study from the German Registry for Stem Cell Transplantation. Transplant Cell Ther. 2024;30:1011.e1\u2013.e13.","journal-title":"Transplant Cell Ther"},{"key":"2778_CR3","doi-asserted-by":"publisher","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 Clinical Trial. Transplant Cell Ther. 2021;27:483.e1\u2013.e6.","journal-title":"Transplant Cell Ther"},{"key":"2778_CR4","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41375-018-0185-y","volume":"32","author":"JA Fein","year":"2018","unstructured":"Fein JA, Shimoni A, Labopin M, Shem-Tov N, Yerushalmi R, Magen H, et al. The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 2018;32:1787\u201394.","journal-title":"Leukemia"},{"key":"2778_CR5","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"2778_CR6","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1200\/JCO.2013.53.8157","volume":"32","author":"ML Sorror","year":"2014","unstructured":"Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol. 2014;32:3249\u201356.","journal-title":"J Clin Oncol"},{"key":"2778_CR7","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1016\/j.bbmt.2015.04.002","volume":"21","author":"JE Vaughn","year":"2015","unstructured":"Vaughn JE, Storer BE, Armand P, Raimondi R, Gibson C, Rambaldi A, et al. Design and validation of an augmented Hematopoietic Cell Transplantation-Comorbidity Index comprising pretransplant Ferritin, Albumin, and platelet count for prediction of outcomes after allogeneic transplantation. Biol Blood Marrow Transpl. 2015;21:1418\u201324.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2778_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41409-019-0703-1","volume":"55","author":"T Luft","year":"2020","unstructured":"Luft T, Benner A, Terzer T, Jodele S, Dandoy CE, Storb R, et al. EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transpl. 2020;55:553\u201361.","journal-title":"Bone Marrow Transpl"},{"key":"2778_CR9","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.bbmt.2018.05.005","volume":"24","author":"R Shouval","year":"2018","unstructured":"Shouval R, de Jong CN, Fein J, Broers AEC, Danylesko I, Shimoni A, et al. Baseline renal function and albumin are powerful predictors for allogeneic transplantation-related mortality. Biol Blood Marrow Transpl. 2018;24:1685\u201391.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2778_CR10","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1182\/bloodadvances.2021004319","volume":"6","author":"R Shouval","year":"2022","unstructured":"Shouval R, Fein JA, Cho C, Avecilla ST, Ruiz J, Tomas AA, et al. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. Blood Adv. 2022;6:1525\u201335.","journal-title":"Blood Adv"},{"key":"2778_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/ejh.13869","volume":"110","author":"F Schierbeck","year":"2023","unstructured":"Schierbeck F, Mortensen J, Andersen NS, Friis LS, Kornblit B, Petersen SL, et al. Pulmonary function is a strong predictor of 2-year overall survival and non-relapse mortality after allogenic hematopoietic cell transplantation. Eur J Haematol. 2023;110:50\u20139.","journal-title":"Eur J Haematol"},{"key":"2778_CR12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/cancers16030515","volume":"16","author":"G Weise","year":"2024","unstructured":"Weise G, Massoud R, Krause R, Heidenreich S, Janson D, Klyuchnikov E, et al. Development and validation of a concise objectifiable risk evaluation score for non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Cancers (Basel). 2024;16:515.","journal-title":"Cancers (Basel)"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02778-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02778-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:56:10Z","timestamp":1772808970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02778-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2778"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02778-w","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.W. received a research grant from Novartis and honoraria from Novartis, Incyte, Sanofi, Therakos, Neovi and Behring. C.R. received a research grant from Jazz Pharmaceuticals; lecture fees and advisory boards with honoraria from Jazz Pharmaceuticals, AbbVie, Servier; financial travel support from Jazz Pharmaceuticals, AbbVie, Medac, BMS Celgene.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (protocol code: 2022-100964-BO-ff; date of approval: 30 January 2023). Informed consent is not necessary for this retrospective study in accordance with \u00a7 12 of Hamburg Hospital law.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}